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Abstract
Background: A critical role for the gut epithelium lies in its ability to discriminate between pathogens and commensals and
respond appropriately. Dysfunctional interactions between microbes and epithelia are believed to have a role in
inflammatory bowel disease (IBD). In this study, we analyzed microbiota and gene expression in IBD patients and examined
responses of mucosal biopsies to bacterial DNA.
Methods: Biopsies were taken from non-inflamed areas of the colon in healthy controls (HC) and Crohn’s disease (CD) and
ulcerative colitis (UC) patients in remission. Biopsies were snap-frozen or cultured with DNA from Lactobacillus plantarum
(LP) or Salmonella dublin (SD). Gene expression was analyzed under basal conditions and in response to DNA. Gene
networks were analyzed using Ingenuity Pathways software. Mucosal-associated microbiota was analyzed using terminal
restriction fragment length polymorphism. Frequency of single nucleotide polymorphisms in NOD2 and TLR9 was assessed.
Results: Patients with IBD had altered microbiota, enhanced expression of inflammatory genes, and increased correlations
between specific gene expression and microbes. Principle component analysis showed CD and UC patients to cluster
independently from healthy controls in both gene expression and microbial analysis. DNA from LP stimulated anti-
inflammatory pathways in controls and UC patients, but induced an upregulation of IL17A in CD patients. There were no
differences in SNP frequencies of TLR9 or NOD2 in the groups.
Conclusions: Patients with Crohn’s disease exhibit altered responses to bacterial DNA. These findings suggest that the gut
response to bacterial DNA may depend not only on the specific type of bacterial DNA, but also on the host.
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Introduction
Inflammatory bowel diseases, including Crohn’s disease (CD)
and ulcerative colitis (UC), are chronic relapsing disorders that are
thought to occur as a result of a loss of tolerance to normal
commensal microbiota [1]. The recent discoveries of a role for
NOD2 and ATG16L1 genes as risk factors have emphasized how
defects in the innate recognition and response to microbial
compounds can influence disease and result in immune dysreg-
ulation and microbial dysbiosis. Patients with CD exhibit a
decrease in bacterial diversity and a dysbiosis with reduced
amounts of protective strains such as Faecalibacterium prausnitzii [2]
and increased levels of inflammatory strains such as adherent
invasive E. coli [3–6]. While the role for intestinal bacteria in the
pathogenesis of IBD is strongly suggested by clinical and
experimental evidence, it is equally clear that not all bacteria
induce intestinal inflammatory responses and that some strains,
such as F. prausnitzii, can actually reduce and modulate intestinal
inflammation [2]. The use of specific strains of probiotics to
modulate and reduce gut inflammation in patients with IBD has
resulted in positive clinical trials for UC, but interestingly, not for
CD [7]. The reason for this is currently unknown; however, it is
possible that either the genetic background and/or an altered
luminal environment might significantly alter the gut response to
probiotics.
In the gut, bacterial DNA is recognized by toll-like receptor 9
(TLR9) on epithelial and immune cells and by the intracellular
inflammasome. TLR9 is located on the apical and the basolateral
membrane of epithelial cells and cellular responses to bacterial
DNA are dependent upon both the site of stimulation as well as by
the CpG sequences [8,9]. We have previously shown that
stimulation of intestinal epithelial cells with bacterial DNA from
a pathogenic strain such as Salmonella dublin results in an
inflammatory response and enhanced secretion of IL-8, while
bacterial DNA from commensal or probiotic strains elicits no
response [9]. Additionally, we have shown in an in vitro model that
the presence of pro-inflammatory cytokines can significantly alter
epithelial and immune cell responses to bacterial DNA [10],
suggesting a role for environmental factors in modulating TLR9
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probiotics have been linked with TLR9 signaling in the gut,
suggesting a dominant role for TLR9 and bacterial DNA in
mediating effects of probiotics [11,12]. In that IBD patients have
both altered gut microbiota and an inflammatory milieu within the
lamina propria, we hypothesized that IBD patients would not
respond to bacterial DNA in a similar fashion as healthy controls.
To test this hypothesis, we characterized the gut microenviron-
ment with regards to basal gene expression and mucosal-
associated microbiota in colonic biopsies from IBD patients and
analyzed the tissue response to probiotic and pathogenic bacterial
DNA. In support of our hypothesis, we show different gene
networks are stimulated in IBD patients in response to bacterial
DNA compared with healthy controls, and further, that these
differences are associated with both altered gut microbiota and
basal gene expression.
Methods
Patient Population
Biopsies were obtained from macroscopically normal areas of
the transverse colon in patients with endoscopic and histologic
confirmed diagnosis of UC for at least one year, or patients with a
similar diagnosis of CD of at least three months’ duration. Patients
were excluded if they had a history of dysplasia of the colon or any
cancer in the last five years, serious underlying disease other than
UC/CD, and/or severely impaired liver or renal function.
Biopsies from healthy controls were obtained from patients
undergoing colonoscopy for screening purposes. Biopsies were
either frozen immediately or placed in 0.5 ml of sterile cell culture
media and transferred to an incubator. Adjacent biopsies were
taken for routine histopathological examination. All patients were
informed about the study and provided written consent. The study
was approved by the University of Alberta ethics committee
(Pro00001799).
Bacterial strains and Preparation of DNA
Salmonella dublin strain Lane (ATCC #15480) was chosen as a
representative pathogen and Lactobacillus plantarum MB 452
(VSL#3 Pharmaceuticals) as a representative probiotic strain for
these studies as we have previously shown significantly different
responses to isolated DNA from these strains in cell culture models
[9]. Strains were grown overnight at 37uC under aerobic
conditions in Luria-burtini (LB) broth (BD 244620) and under
anaerobic conditions in Lactobacilli MRS broth (BD 288130),
respectively. DNA was isolated as previously described [9].
Culture of Biopsies
Whole-thickness biopsies (5–10 mg) were placed in culture filter
plates at 37uC in 1 ml of RPMI 1640 media (100 U/ml penicillin,
100 ug/ml streptomycin, and 50 ug/ml gentamycin) and cultured
for 2 hours650 ug/ml DNA isolated from Salmonella dublin or
Lactobacillus plantarum. After incubation, tissues were harvested in
RNAlater and stored at 280uC.
Microbial Analysis
Microbes associated with the biopsies were assessed using
terminal restriction fragment length polymorphism (T-RFLP).
Total DNA was extracted from biopsies using a FastDNA Spin Kit
(MP Biomedical) as per manufacturer’s instructions. 16S rRNA
was amplified by PCR using a 6-FAM-59-labelled, broad-range
forward primer 6-FAM-8F (Applied Biosystems), 59-AGAGTTT-
GATCCTGGCTCAG-39) and a broad-range reverse primer
926R (Applied Biosystems) (59-AGAAAGGAGGTGATC-
CAGCC-39). PCR was performed with 50 ng DNA. Cycling
conditions consisted of an initial denaturing step at 94uC for 2 min
followed by 35 cycles of 94uC 1 min, 56uC 1 min, 72uC 1 min,
and a final 10 min extension at 72uC. A DNA-free template
control was included in every PCR run and amplification
confirmed by visualization of a single 920 kb PCR product on a
1% agarose gel. Amplicons were purified using Qiagen MinElute
PCR Purification Kit as per the manufacturer’s instructions.
Amplicon DNA (200–300 ng, as determined by Nanodrop
spectrophotometer measurement (Thermo Scientific, Wilmington,
Delaware, USA) was digested with the Hpall restriction enzyme
(Promega, Madison, Wisconsin, USA) for 16 hours at 37uC. For
each sample, 100 ng of HPAII digested fragments were resolved in
duplicate using a 3130XL Genetic Analyzer (Applied Biosystems,
Carlsbad, California, USA). Each sample was separated with an
internal ROX1000 DNA marker to enable fragment length
normalization. Bionumerics 6.0 software (Applied Maths, Sint-
Martens-Latem, Belgium) was used to normalize fluorescently
labeled terminal fragment lengths and select peaks of interest.
Selected peaks of interest were associated, in silico, with fragment
lengths of known bacteria using Microbial Community Analysis 3
(MiCA; Shyu, 2007) and Ribosomal Database Project v.9 (RDP;
Cole, 2009). Peaks corresponding to fragments between 25 and
650 base pairs (bp) in length were used in the community
composition and cluster analyses. Principal component and
clustering analyses were done to map each individual patient
based upon their microbial profile and to define specific clusters.
TaqMan Low Density Array (TLDA) and Correlation
Analysis
Total RNA was isolated from cultured and snap-frozen biopsies
using a modified TRIzol extraction (Invitrogen, USA) followed by
an extra purification using RNeasy columns (Qiagen, USA).
Briefly, tissue was homogenised in 1 ml TRIzol then mixed with
200 ml of chloroform and centrifuged at 14000 rpm to separate
the aqueous layer. This RNA-containing layer was doubled in
volume with 70% ethanol and applied to an RNeasy column by
centrifugation as per manufacturer’s instructions. Total RNA
quantity and integrity were evaluated using a nanodrop 1000
spectrophotometer (Thermo Scientific) and Flashgel system
(Lonza, Basel, Switzerland). Relative gene expression was analyzed
using 96-plex Human Immune TaqMan Low Density Arrays
(TLDA)(Applied Biosystems). cDNA was created using random
hexamers and the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems) as per manufacturer’s instructions. The
relationship between host gene expression and microflora was
investigated using Spearman rank correlations. Correlations with
an FDR#5% were considered significant.
Single nucleotide polymorphisms
The presence of single nucleotide polymorphisms (SNPs) in
NOD2 and TLR9 was assessed [13,14]. Three SNPs were
analysed using either single-direction-sequencing for TLR9-
1237T/C (rs5743836) and NOD2 SNP13 3020insC (rs2066847)
or using SNaPshot Multiplex system (Applied Biosystems) for
NOD2 SNP8 2104C/T. Primer sequences are described in Table
S1.
Gene networks
In order to determine biological relevance from the gene
expression data, probable gene networks were analyzed using the
Ingenuity Pathways Analysis application (Ingenuity Systems,
Redwood City, CA). The genes considered were those that were
IBD and Bacterial DNA
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treatment group when compared to the control. The relationship
between the genes, which are represented by nodes, is denoted by
an edge. Red and green nodes represent up- and down-regulated
gene expression respectively. Direct interactions between genes are
represented by solid lines.
Statistical analysis
For the study groups, continuous variables were analyzed using
t tests. Tests for normality (Kolmogorov–Smirnov) were applied
and median values and non-parametric tests (Mann–Whitney U)
were used for data that were not normally distributed. For
dichotomous variables, differences between groups were compared
using x
2 or Fisher exact tests.
Results
Demographic and clinical data of the patient cohort
Biopsies were obtained from adult patients with CD (n=15),
UC (n=14) or healthy controls (n=21) (Table 1). There were no
significant differences between the groups in age, gender, or
disease duration. All IBD patients were currently in remission. The
majority of the IBD patients were receiving drug therapy,
including 5-ASA, antibiotics, steroids, immunomodulators, or
biologics.
Basal Gene Expression and Microflora Composition
Gene expression and microbial composition were analyzed in
snap-frozen colonic biopsies in order to determine if the
microenvironment differed in control tissue compared with
macroscopically non-inflamed tissue from CD and UC patients.
Analysis of mucosa-associated microbiota showed no significant
differences in the main phyla between the groups (Table 2).
However, altered microbial composition within phyla (Table 2)
and differentially expressed genes (fold-change $1.5) (Table 3)
were identified between the healthy controls and patients with CD
and UC.
Ulcerative Colitis. Genes up-regulated under basal condi-
tions included cytokines (IL1A, IL1B, IL4, IL6, IL8, IL17, CSF2,
CSF3), chemokines (CXCL11, CCL19), secreted factors (NOS2A),
and molecules related to cellular migration (SELE, SELP). Genes
down-regulated included cytokines (IL13, CSF1,), chemokines
(CCL3, CCL5) and molecules involved in intracellular signalling
(SMAD7, BCL2, CYP7AI, AGTR1), and apoptosis (FASLG).
These results suggest a heightened inflammatory-type environ-
ment in tissue from UC patients, with increased mRNA for pro-
inflammatory cytokines, chemotactic factors, cellular markers
involved in T cell activation, and adhesion molecules, along with
decreased mRNA of markers of apoptosis and cytotoxic T cells. In
addition to altered gene expression, UC patients also had changes
in mucosal-associated microbiota (Table 2).
Crohn’s Disease. CD patients exhibited increased expres-
sion of several genes related to inflammation, including cytokines
(IFNG, IL12RA, IL1A, IL1B, IL4, IL6, IL8, IL17, CSF3, TNF),
chemokines (CXCL10, CXCL11, CCR4, CCL19), secreted
factors (NOS2A), and molecules related to cellular migration
(REN, ICAM1, SELE, SELP). Genes down-regulated included
cytokines (IL13), chemokines (CCL5) and molecules involved in
intracellular signalling (AGTR1) and apoptosis (FASLG). Micro-
bial analysis revealed that samples from CD patients had altered
gut microbiota in comparison with controls and UC patients
(Table 2).
Principal Component Analysis (PCA) and Correlation
Matrix
Orthogonal partial least-squares discriminant analysis (OPLS-
DA) of gene expression showed UC patients to cluster indepen-
dently from CD and controls (Figure 1A) with gene expression of
CSF3 (colony stimulating factor 3), IL-17, and HLA-DRB1
primarily driving the separations. OPLS-DA analysis of microbi-
ota also showed CD and UC patients to cluster independently
from controls. Both positive and negative correlations between
gene expression and specific microbial groups were seen in all
groups (Figure 2). However, both CD and UC patients had more
positive and less negative correlations as compared with controls.
Table 1. Clinical parameters of patients.
Category Sub-Category Control (n=21) Crohn’s Disease (n=15) Ulcerative Colitis (n=14)
Mean Age (yrs)(range) 45.6(20–81) 38.3(21–54) 46(20–73)
Gender Female 8 (38%) 4 (27%) 4 (29%)
Male 13 (62%) 11 (73%) 10 (71%)
Disease Site Colonic n/a 4 (27%) 14 (100%)
Ileocolonic 5 (33%)
Ileal 4 (27%)
Undetermined 2 (13%)
Disease Duration (yrs) n/a 12 (1–24) 15 (1–33)
Medication 5-ASA n/a 4 (27%) 11 (79%)
Steroids 4 (27%) 4 (29%)
Immunomodulators* 6 (40%) 4 (29%)
Biologics 4 (27%) 0 (0%)
Antibiotics 0 (0%) 0 (0%)
None 1 (7%) 1 (7%)
*Immunomodulators: azathioprine and/or infliximab.
5-ASA- 5-amino salicylic acid.
doi:10.1371/journal.pone.0037932.t001
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inantly found within the Bacteroidetes phyla. These results clearly
demonstrate altered microbial-host relationships exist in patients
with both CD and UC, and further, these altered relationships
exist in the absence of histological disease in patients in clinical
remission.
Gene Expression in Response to Bacterial DNA
Having determined that the gut luminal environment differed
between IBD patients and healthy controls, we sought to
determine if the patient groups differed in their response to
bacterial DNA. Biopsies from an age matched subset of CD (n=6)
and UC (n=6) patients and controls (n=6) (Table 4) were
cultured for two hours in the presence or absence of bacterial
DNA (S. dublin or L. plantarum) and early changes in gene
expression were analyzed (Table 5).
Controls. A total of 9 genes showed a $1.5 fold change in
response to bacterial DNA, with 2 gene responses specific to L.
plantarum and 4 specific to S. dublin. Gene responses similar to both
bacterial DNAs included an up-regulation of lymphotoxin a
(LTA), CCR2, CD19, and CD40LG. Specific responses to L.
plantarum included an up-regulation of IL10 and a down-regulation
of IL4. Specific responses to S. dublin included an up-regulation of
IL5, CCR7, and TNFRSF18 and a down-regulation of IL13.
Ulcerative Colitis. In UC patients, a total of 20 genes
showed a fold change of $1.5 to bacterial DNA, with 7 gene
responses specific to L. plantarum and 4 specific to S. dublin. Again,
several gene responses were similar to both bacterial DNAs, and
included a down-regulation of IL5, LTA, and an up-regulation of
AGTR1 and IL1A. Specific responses to L. plantarum included a
down-regulation of IL12B, CCR2, FASLG, TFRC, and an up-
regulation of CXCR3, TBX21, and REN. Specific responses to S.
dublin included a down-regulation of CD3E and an up-regulation
of CCL19, CXCL10, and CXCL11.
Crohn’s Disease. In CD patients, a total of 18 genes showed
a fold change of $1.5 to bacterial DNA, with 4 gene responses
specific to L. plantarum and 8 specific to S. dublin. Responses similar
to both bacterial DNAs included a down-regulation of IL13,
HLADRB1, TNFRSF18, and C3, and an up-regulation of IL17
and REN. Specific responses to L. plantarum included a down-
regulation of IL6 and IFN1. CD patients were generally more
responsive to S. dublin compared with either controls or UC
patients, with an upregulation of IL1A, IL1B, IL8, CCL3,
CXCL11, and a down-regulation of CCL19 and CD19.
Gene Networks of DNA-treated and Control Biopsies
Alterations in gene expression in the cultured biopsies were
entered into the Ingenuity Pathway Analysis (IPA) database and
functional networks identified in order to provide biological
context to the differentially expressed genes (Figures 3,4,5). This
approach allows for changes in gene expression to be related to
functional changes within cellular pathways. Early tissue responses
to S. dublin in control patients (Figure 3) were linked with
chemokine and cytokine responses along with NF-kB and STAT6
signaling pathways. In contrast, the response of control patients to
L. plantarum (Figure 3) involved an up-regulation of IL-10 and
involvement of STAT3 and STAT6 pathways, indicative of an
anti-inflammatory response. This would be in agreement with our
previous studies showing DNA from probiotic strains to have a
differential effect on epithelial and immune responses compared
with DNA from pathogenic strains [9]. Biopsies from UC patients
had a similar response compared with controls to S. dublin
(Figure 4). Interestingly, in UC patients, L. plantarum DNA reduced
IL12B and FASLG expression, with an involvement of NF-kB and
STAT1 pathways, suggesting that this probiotic strain may have
Table 2. Microbial analysis of biopsies from healthy controls and CD and UC patients.
Phyla Class Control (n=21) CD(n=15) UC(n=14)
Firmicutes % of Total 70610 (49–91) 71611 (49–89) 73612 (55–94)
Clostridia* 9365 (72–99) 9167 (77–98) 9563 (88–99)
Erysipelotrichi* 261 (0.1–5) 363 (0–10) 362 (0–8)
Bacilli* 162 (0–7) 161 (0–5) 161 (0–4)
Bacteroidetes % of Total 2269 (9–37) 21612 (1–45) 20611 (3–45)
Bacteroidia* 52612 (30–71) 56618 (28–99) 46611 (34–71)
Sphingobacteria* 162 (0–7) 161 (0–4) 262 (0–7)
Flavobacteria* 263 (0.1–12) 465 (0–17) 564 (0–13)
Proteobacteria % of Total 363 (0.1–15) 262 (0.3–6) 261 (0–6)
Alphaproteobacteria* 4611 (0–50) 8615
a (0–53) 363 (0–9)
Betaproteobacteria* 20616 (0–67) 19618 (0–74) 20626 (0–100)
Deltaproteobacteria* 666 (0–24) 16619
a (0–68) 669 (0–32)
Gammaproteobacteria* 68622 (21–100) 56626 (17–88) 63632 (0–96)
Actinobacteria Actinobacteria 261 (0.1–5) 261 (0.4–6) 261 (0–5)
Fusobacteria Fusobacteria 0.160.3 (0–1) 0.160.1 (0–0.3) 0.361 (0–3)
Spirochaetes Spirochaetes 0.560.4 (0.1–1) 0.460.4 (0–1) 0.360.4 (0–1)
Tenericutes Mollicutes 0.962 (0–7) 161 (0–5) 0.860.7 (0–2)
Verrucomicrobia Verrucomicrobiae 0.160.2 (0–1) 0.160.2 (0–1) 0.160.1 (0–1)
*: represents % of phyla.
Values are given as means 6 SEM with range.
a,0.05 compared with Control and UC.
doi:10.1371/journal.pone.0037932.t002
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Function Symbol Gene Fold change
CD UC
Cytokine CSF1 Colony-stimulating factor 1 21.53
CSF2 Colony-stimulating factor 2 1.65 1.66
CSF3 Colony-stimulating factor 3 3.58 3.83
IFNG Interferonc 2.79
IL1A Interleukin 1a 7.50 4.70
IL1B Interleukin 1b 5.28 3.51
IL2 Interleukin 2 1.51
IL2RA interleukin 2 receptor alpha 2.15
IL4 Interleukin 4 3.05 6.44
IL5 Interleukin 5 21.64
IL6 Interleukin 6 2.37 1.59
IL8 Interleukin 8 3.97 12.60
IL-13 Interleukin 13 22.46 21.56
IL17 Interleukin 17 2.84 18.61
LTA Lymphotoxin alpha 1.65
TNF Tumor necrosis factor 1.61
Chemokine CCL2 Chemokine (C-C motif) ligand 2 1.73
CCL3 Chemokine (C-C motif) ligand 3 1.62
CCL5 Chemokine (C-C motif) ligand 5 21.98
CCL19 Chemokine (C-C motif) ligand 19 2.35 1.63
CCR4 Chemokine (C-C motif) receptor 4 2.57
CXCL10 Chemokine (C-X-C motif) ligand 10 5.59
CXCL11 Chemokine (C-X-C motif) ligand 11 14.42 2.02
Cellular Marker CD3E CD3e molecule, epsilon 21.58
CD8A CD8a molecule 21.82 21.91
CD40 CD 40 molecule 1.61
CD40LG CD 40 ligand 2.54
CD68 CD68 molecule 1.54
CTLA4 Cytotoxic T-lymphocyte-associated protein 4 1.91 1.92
HLA-DRB1 Major histocompatibility complex, class II, DR beta 1 14.42 37.59
SKI Sarcoma viral oncogene homolog 21.59
TBX21 T-box 21 21.74
TNFRSF18 Tumor necrosis factor receptor superfamily, member 18 1.71
Intracellular Signaling AGTR1 Angiotensin II receptor, type 1 22.73 21.51
SMAD7 SMAD family member 7 21.74
Secreted Factors NOS2A Nitric oxide synthase 2, inducible 2.05 4.85
Apoptosis FASLG Fas ligand 21.83 21.95
BCL2 B-cell CLL/lymphoma 2 21.57
Enzymes ACE Angiotensin I converting enzyme 21.52
CYP7A1 Cytochrome P450, family 7, subfamily A 1.57 22.20
PTGS2 Prostaglandin-endoperoxide synthase 2 2.29
Cellular Migration FN1 Firbronectin 1 21.51
ICAM1 Intercellular adhesion molecule 1 1.77
SELE Selectin E 2.66 4.66
SELP Selectin P 1.95 1.89
Degranulation, Compliment C3 Complement component 3 1.82
GNLY Granulysin 21.51
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When examining the response of CD patients to S dublin DNA, a
much different response was seen. As seen in Figure 5, gene
networks activated in response to S. dublin DNA included the
IL17A, IL18, IL6, and IL8 pathways along with NF-kB.
Furthermore, the response of CD biopsies to L. plantarum DNA
did not include any anti-inflammatory pathways, but instead
involved an up-regulation of pathways including IL17A and pro-
inflammatory cytokines (Figure 5).
Table 3. Cont.
Function Symbol Gene Fold change
CD UC
PRF1 Perforin 1 21.72
Other EDN1 Endothelin 1 21.66
TFRC Transferring receptor 1.53
doi:10.1371/journal.pone.0037932.t003
Figure 1. Orthogonal partial least-squares discriminant analysis (OPLS-DA) plot of gene transcripts (A) and microbiota (B) of
controls (green circles), UC (red triangles) and CD (blue squares) patients. (A) Network analysis based on 96 differentially expressed genes
between groups using an OPLS-DA model showed CD and UC patients to cluster independently from controls. (B) Analysis of mucosal-associated
bacteria in snap-frozen biopsies also showed CD and UC patients to cluster independently from controls.
doi:10.1371/journal.pone.0037932.g001
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As gene expression and cytokine secretion reflect a combined
response from both epithelial and immune cells, the changes in
expression could be due to altered numbers of immune cells
present in the biopsies. However, there were no significant
differences between patient groups in expression of the T cell
markers, CD4, CD8A and CD3E, the B cell marker, CD19, or the
monocyte/macrophage marker CD68 (Table 6). This would
suggest that the different responses to bacterial DNA seen in IBD
patients likely could not be attributed to population differences in
epithelial and immune cells in the biopsies.
TLR9 and NOD2 Genotyping
Studies have shown TLR9 polymorphisms to be associated with
CD and specific TLR9 polymorphisms to be associated with
altered TNFa and/or IFNc levels [14,15,16,17]. In addition, one
Figure 2. Correlations between microbiota and gene expression showing both positive and negative relationships. Microbes are
classified as by phyla and genera. Genes are organized into functional groups. Bact: Bacteroides; Firm: Firmicutes; Prot: Proteobacteria. Black squares
represent positive correlations (r.0.45); grey squares show no significant correlation; white squares represent negative correlations (r,0.45).
doi:10.1371/journal.pone.0037932.g002
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NOD2 variants in patients with CD [18]. In view of these findings,
we examined frequencies of these genes to determine if a
functional difference in responsiveness to bacterial DNA could
be linked with the presence of particular alleles. The genotype
frequencies of the TLR9-1237 alleles did not differ between the
three groups; however, the rare alleles of both NOD2 SNPs were
found more often in the CD patients (Table 7). All frequencies
were similar to what has previously been published [18]. No
patient had both NOD2 rare alleles or had NOD2 SNP8 and
TLR9-1237 SNPs together. Two patients with CD were
heterozygotes for the alleles of both NOD2 SNP13 and TLR9-
1237 SNPs. There was no apparent relationship between TLR9
polymorphisms and IFNc gene expression. There was also no
difference in the level of TLR9 expression between the groups
(data not shown).
Discussion
In this study, we show that the luminal microenvironment in the
transverse colon differs between IBD and control patients in
patients in remission and in areas of no histological inflammation.
IBD patients had enhanced gene expression of pro-inflammatory
cytokines and chemokines and this was associated with a dysbiosis
in mucosal-associated microbiota. Correlation analysis showed
that IBD patients had increased number of positive correlations
between specific gene expression and select microbes compared
with controls. Furthermore, this heightened inflammatory envi-
ronment was associated with altered transcriptional responses to
bacterial DNA. In particular, CD patients responded to DNA
from both S. dublin and L. plantarum with enhanced IL17 gene
expression. This was in contrast to controls and UC patients,
where probiotic DNA stimulated anti-inflammatory pathways and
the pathogenic DNA stimulated immune responses. This would
suggest that the gut epithelium may have lost the ability to
distinguish between bacterial DNA in patients with CD.
In taking of biopsies for study, we were careful to obtain biopsies
only in patients who were in remission in order to limit alterations
in responses due to active inflammatory processes. However, even
in the absence of disease, altered basal gene expression was seen in
tissue from both UC and CD patients when compared with
controls. In biopsies from CD patients, several Th1-specific IFN-
induced chemokines (eg CXCL10, CXCL11) as well as IFNG
were up-regulated, indicative of a Th1 type environment. In
contrast, IFNG was normal in UC patients, while IL4 was up-
regulated, indicative of a more Th2-like cytokine response. Similar
to what has previously been shown [19,20] both CD and UC
patients had up-regulated colonic IL17 mRNA expression.
Interestingly, IL17 mRNA was actually higher in UC patients
compared with CD patients; however, we did not measure IL-17
protein levels to confirm higher IL-17 production in CD patients.
Correlation analysis between gene expression and microbiota
demonstrated interesting results with respect to which genes were
predominantly correlated with specific microbial taxa. Overall,
Table 4. Clinical parameters for patients in response to bacterial DNA experiments.
Category Sub-Category Control (n=6) Crohn’s Disease (n=6) Ulcerative Colitis (n=6)
Mean Age (yrs) (range) 49.3(18–66) 44.0(23–68) 40.2(24–72)
Gender Female 3 (50%) 4 (66%) 2 (34%)
Male 3 (50%) 2 (34%) 4 (66%)
Disease Duration (yrs) n/a 8 (5–22) 5 (4–8)
Medication 5-ASA n/a 2 (33%) 5 (83%)
Steroids 0 (0%) 2 (33%)
Immunomodulators* 2 (33%) 0 (0%)
Biologics 1 (16%) 0 (0%)
Antibiotics 0 (0%) 0 (0%)
None 2 (33%) 1 (16%)
*Immunomodulators: azathioprine and/or infliximab.
5-ASA- 5-amino salicylic acid.
doi:10.1371/journal.pone.0037932.t004
Table 5. Gene expression changes (.1.5 fold) in biopsies from CD and UC patients in comparison with controls in response to
bacterial DNA.
Group Treatment Increased Decreased
Control(n=6) L. plantarum CD19, CYP7AI, LTA, CCR2, CD40LG, IL10 IL4
S. dublin CYP7A1, CD19, LTA, CCR7, IL5, CCR2, TNFRSF18, CD40LG IL13
CD(n=6) L. plantarum REN, IL-17, AGTR1, CYP7A1 IL4, TBX21, IL6, TNFRSF18, IL13, HLA-DRB1, FN1, C3
S. dublin CCL3, IL-17, IL-1A, CXCL11, CYP7A1, REN, IL1B, IL8 IL4, CCL19, TNFRSF18, CD19, HLA-DRB1, C3, CCR7,
IL-13
UC(n=6) L. plantarum REN, IL-1A, TBX21, AGTR1, IL-4, CXCR3 CCR2, IL5, LTA, IL-12B, FASLG, TNFRSF18, TFRC
S. dublin CCL19, TNFRSF18, CXCL10, IL1A, AGTR1, CXCL11 CD3E, LTA, IL5
doi:10.1371/journal.pone.0037932.t005
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numbers of positive correlations between particular microbial
groups and inflammatory gene expression. The significance of
these findings remains to be determined; however, this increased
correlation between gene expression and particular microbial
communities in IBD patients may reflect an increased exposure of
the host immune system to luminal microbes. In addition, the
clustering of correlations between numerous genes and Bacter-
oidetes in the CD patients may represent selective responses in
these particular patients. Alternatively, these altered correlations
may reflect the presence or absence of particular microbial strains.
These results differ from those recently published by Lepage et al
[21], who demonstrated a lower number of correlations in patients
with UC. However, in their study, they examined a much larger
number of genes (21,747) in comparison with our study. In
addition, differences in biopsy location (sigmoid vs transverse) may
also have contributed.
In epithelial cells, bacterial DNA interacts with TLR9 on the
apical or basolateral membrane and both the type of bacterial
DNA and the site of interaction can influence cellular responses
Figure 3. Ingenuity Pathway gene network. The most highly significant gene networks identified in the Ingenuity Pathway analysis of the gene
expression data in response to bacterial DNA are shown. Control patient responses to DNA from L. plantarum are shown in (A) and to S. dublin in (B).
Networks are displayed graphically as nodes (genes/gene products) and edges (the biological relationships between the nodes). The intensity of the
node color indicates the degree of up (red) or down (green) regulation in gene expression. Nodes are displayed using shapes that represent the
functional class of the gene product. Edges are displayed as a direct interaction (solid line).
doi:10.1371/journal.pone.0037932.g003
Figure 4. Ingenuity Pathway gene network. The most highly significant gene networks identified in the Ingenuity Pathway analysis of the gene
expression data in response to bacterial DNA are shown. UC patient responses to DNA from L. plantarum are shown in (A) and to S. dublin in (B).
Networks are displayed graphically as nodes (genes/gene products) and edges (the biological relationships between the nodes). The intensity of the
node color indicates the degree of up (red) or down (green) regulation in gene expression. Nodes are displayed using shapes that represent the
functional class of the gene product. Edges are displayed as a direct interaction (solid line).
doi:10.1371/journal.pone.0037932.g004
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some in epithelial and immune cells, resulting in IL-1b and IL-18
secretion [22]. In our experimental system, intact whole biopsies
would have included epithelial cells, along with possibly T and B
cells, dendritic cells, macrophages, neutrophils, and other innate
immune cells. Gene expression measured would therefore be a
combination of all cell types and we are not able to differentiate
between an epithelial and an immune cell response. However, the
advantage to this system is the fact that overall gene expression
represents a more physiological response to stimuli than would be
seen if only isolated cells were stimulated. Furthermore, by
studying whole biopsies, we could somewhat reduce interactions of
bacterial DNA with the basolateral surface of epithelial cells,
which is known to elicit different responses. In order to determine
if the number of immune cells were different between the groups,
we measured the expression of specific T and B cell markers, and
found no differences. These findings would suggest that the altered
gene expression was not likely due to increased numbers of
immune cells in the biopsies from IBD patients.
A surprising and interesting finding in these studies was the
response of biopsies from patients with CD to DNA from L.
plantarum. While control responses included the induction of
STAT3, which positively regulates IL-10 and maintains epithelial
barrier function (15), responses to L. plantarum in CD patients
included enhanced IL17A expression and gene network analysis
suggested an involvement of high-mobility group protein
(HMGB). HMGB is released from activated macrophages and
monocytes and can drive inflammatory reactions through inter-
Figure 5. Ingenuity Pathway gene network. The most highly significant gene networks identified in the Ingenuity Pathway analysis of the gene
expression data in response to bacterial DNA are shown. CD patient responses to DNA from L. plantarum are shown in (A) and to S. dublin in (B).
Networks are displayed graphically as nodes (genes/gene products) and edges (the biological relationships between the nodes). The intensity of the
node color indicates the degree of up (red) or down (green) regulation in gene expression. Nodes are displayed using shapes that represent the
functional class of the gene product. Edges are displayed as a direct interaction (solid line).
doi:10.1371/journal.pone.0037932.g005
Table 6. Expression levels of immune cell markers in biopsies from CD and UC patients as compared with controls in response to
DNA experiments.
Marker Target Gene Group Fold Change D Expression (Log10 RQ) p-value
T cell CD3E CD 21.58 20.20 0.39
UC 21.25 20.10 0.69
CD4 CD 1.42 0.15 0.37
UC 21.42 20.15 0.09
CD8A CD 21.82 20.26 0.20
UC 21.91 20.28 0.09
B cell CD19 CD 1.36 0.13 0.59
UC 21.23 20.09 0.76
Monocyte/Macrophage CD68 CD 1.54 0.19 0.26
UC 21.15 20.06 0.42
doi:10.1371/journal.pone.0037932.t006
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(Receptor for Advanced Glycan Endproducts) [23]. It is interesting
that, to date, probiotic therapy has largely failed in CD patients,
with one trial using Lactobacillus rhamnosus to actually worsen the
disease compared with placebo [7]. Findings from this study
suggest that immune responses to bacterial DNA appear to be
dysfunctional in CD patients, although we cannot differentiate
between a failure to properly recognize bacterial DNA by either
epithelial or immune cells, or alternatively, a failure to respond
appropriately. Overall, regardless of the underlying mechanism,
these findings provide further support to the hypothesis that a
dysfunctional innate recognition and response to molecules of
microbial origin is involved in the pathogenesis of CD in
particular.
In these studies we cannot differentiate between TLR9 signaling
and inflammasome responses as both may be activated upon
exposure to bacterial DNA. The gene encoding for TLR9 is
mapped to chromosome 3p21.3 in the vicinity of a shared
susceptibility locus for CD and UC. Although one study has shown
that the frequency of the 1237 C allele and the C carrier status
were significantly increased in CD patients [14], others have
shown no difference [24]. In our study, we did not observe a
significant increase in this allele in our study population. There
was also no association between NOD2 and TLR9 alleles in our
population groups as has been shown [18]. Responses to bacterial
DNA in our study were not related to the presence of particular
TLR9 or NOD2 polymorphisms or to the altered expression of
TLR9. Although we did not measure levels of TLR9 protein
expression in these studies, it is unlikely that different levels of
expression could explain our results, in that CD and UC patients
did respond to bacterial DNA, but responded with a different
pattern of gene expression. It is also possible that the extensive
drug usage that is characteristic of IBD patients could have
affected individual host responses; however, in that the IBD
patients were all on different types of medication, and the types of
medication were similar between the UC and CD patients, it is
unlikely that particular drug usage could be the predominant
reason for the differential response between UC and CD patients.
In conclusion, patients with IBD have an enhanced level of
interaction between gut microbiota and the intestinal epithelium
which correlates with dysregulated responses to bacterial DNA,
particularly in patients with Crohn’s disease. These results suggest
that the host response to bacterial DNA may depend not only on
the specific type of bacterial DNA encountered, but also on the
particular host.
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